These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 28279838)

  • 1. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
    Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
    Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of sphingosine-1-phosphate in ulcerative colitis.
    Argollo M; Furfaro F; Gilardi D; Roda G; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):413-420. PubMed ID: 32093531
    [No Abstract]   [Full Text] [Related]  

  • 3. [The place of sphingosine-1-phosphate modulators in the therapy of inflammatory bowel diseases].
    Szymaszkiewicz K; Szymaszkiewicz A; Fichna J
    Postepy Biochem; 2020 Mar; 66(1):42-48. PubMed ID: 33320478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
    Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
    Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease.
    Verstockt B; Vetrano S; Salas A; Nayeri S; Duijvestein M; Vande Casteele N;
    Nat Rev Gastroenterol Hepatol; 2022 Jun; 19(6):351-366. PubMed ID: 35165437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
    Scott FL; Clemons B; Brooks J; Brahmachary E; Powell R; Dedman H; Desale HG; Timony GA; Martinborough E; Rosen H; Roberts E; Boehm MF; Peach RJ
    Br J Pharmacol; 2016 Jun; 173(11):1778-92. PubMed ID: 26990079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease.
    Nielsen OH; Li Y; Johansson-Lindbom B; Coskun M
    Trends Mol Med; 2017 Apr; 23(4):362-374. PubMed ID: 28283249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovations in Oral Therapies for Inflammatory Bowel Disease.
    Ma C; Battat R; Dulai PS; Parker CE; Sandborn WJ; Feagan BG; Jairath V
    Drugs; 2019 Aug; 79(12):1321-1335. PubMed ID: 31317509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5.
    Selkirk JV; Bortolato A; Yan YG; Ching N; Hargreaves R
    Front Pharmacol; 2022; 13():892097. PubMed ID: 35784713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.
    Wang J; Goren I; Yang B; Lin S; Li J; Elias M; Fiocchi C; Rieder F
    Aliment Pharmacol Ther; 2022 Feb; 55(3):277-291. PubMed ID: 34932238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unveiling the biological role of sphingosine-1-phosphate receptor modulators in inflammatory bowel diseases.
    Tourkochristou E; Mouzaki A; Triantos C
    World J Gastroenterol; 2023 Jan; 29(1):110-125. PubMed ID: 36683721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etrasimod: First Approval.
    Shirley M
    Drugs; 2024 Feb; 84(2):247-254. PubMed ID: 38388871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine-1-phosphate (S1P) signaling regulates the production of intestinal IgA and its potential role in the pathogenesis of canine inflammatory bowel disease.
    Nakazawa M; Maeda S; Yokoyama N; Nakagawa T; Yonezawa T; Ohno K; Matsuki N
    J Vet Med Sci; 2019 Sep; 81(9):1249-1258. PubMed ID: 31341112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis.
    Bencardino S; D'Amico F; Faggiani I; Bernardi F; Allocca M; Furfaro F; Parigi TL; Zilli A; Fiorino G; Peyrin-Biroulet L; Danese S
    J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling.
    Chew WS; Wang W; Herr DR
    Pharmacol Res; 2016 Nov; 113(Pt A):521-532. PubMed ID: 27663260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine-1 Phosphate Receptor Modulators: The Next Wave of Oral Therapies in Inflammatory Bowel Disease.
    Choden T; Cohen NA; Rubin DT
    Gastroenterol Hepatol (N Y); 2022 May; 18(5):265-271. PubMed ID: 36397756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn's-Like Ileitis by Suppressing Thymocyte Maturation.
    Karuppuchamy T; Tyler CJ; Lundborg LR; Pérez-Jeldres T; Kimball AK; Clambey ET; Jedlicka P; Rivera-Nieves J
    Inflamm Bowel Dis; 2020 Jan; 26(2):216-228. PubMed ID: 31807751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine.
    Dal Buono A; Gabbiadini R; Alfarone L; Solitano V; Repici A; Vetrano S; Spinelli A; Armuzzi A
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications.
    Spampinato SF; Sortino MA; Salomone S
    Adv Pharmacol; 2022; 94():95-139. PubMed ID: 35659378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.